Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease

S. Ruggieri, P. Falaschi, M. Baldassarre, R. D'Urso, G. De Giorgio, A. Rocco, A. Agnoli

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Plasma prolactin (PRL) level modifications after acute administration of L-dopa, L-dopa plus carbidopa and L-dopa benserazide were studied in parkinsonian patients. PRL increase after benserazide was compared with PRL response after carbidopa at the same dosage in untreated parkinsonian patients. A further study of the hyperprolactinemic effect of benserazide was performed in vitro on isolated and dispersed rat pituitary cells. The data gathered indicate that benserazide-induced hyperprolactinemia in parkinsonian patients could be due to a direct effect of the drug at the hypothalamic level and consequently to an inhibition of dopamine decarboxylation in the tuberoinfunbdibular dopaminergic system. It is not possible to exclude, however, that benserazide could exert its biological activity through the production of active metabolites in vivo.

Original languageEnglish
Pages (from-to)102-108
Number of pages7
JournalNeuropsychobiology
Volume8
Issue number2
Publication statusPublished - 1982

Fingerprint

Benserazide
Dopa Decarboxylase
Levodopa
Prolactin
Parkinson Disease
Carbidopa
Hyperprolactinemia
Decarboxylation
Dopamine
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)
  • Psychology(all)

Cite this

Ruggieri, S., Falaschi, P., Baldassarre, M., D'Urso, R., De Giorgio, G., Rocco, A., & Agnoli, A. (1982). Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease. Neuropsychobiology, 8(2), 102-108.

Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease. / Ruggieri, S.; Falaschi, P.; Baldassarre, M.; D'Urso, R.; De Giorgio, G.; Rocco, A.; Agnoli, A.

In: Neuropsychobiology, Vol. 8, No. 2, 1982, p. 102-108.

Research output: Contribution to journalArticle

Ruggieri, S, Falaschi, P, Baldassarre, M, D'Urso, R, De Giorgio, G, Rocco, A & Agnoli, A 1982, 'Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease', Neuropsychobiology, vol. 8, no. 2, pp. 102-108.
Ruggieri S, Falaschi P, Baldassarre M, D'Urso R, De Giorgio G, Rocco A et al. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease. Neuropsychobiology. 1982;8(2):102-108.
Ruggieri, S. ; Falaschi, P. ; Baldassarre, M. ; D'Urso, R. ; De Giorgio, G. ; Rocco, A. ; Agnoli, A. / Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease. In: Neuropsychobiology. 1982 ; Vol. 8, No. 2. pp. 102-108.
@article{6ebdf46c33e7484999d678e7df3dc07c,
title = "Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease",
abstract = "Plasma prolactin (PRL) level modifications after acute administration of L-dopa, L-dopa plus carbidopa and L-dopa benserazide were studied in parkinsonian patients. PRL increase after benserazide was compared with PRL response after carbidopa at the same dosage in untreated parkinsonian patients. A further study of the hyperprolactinemic effect of benserazide was performed in vitro on isolated and dispersed rat pituitary cells. The data gathered indicate that benserazide-induced hyperprolactinemia in parkinsonian patients could be due to a direct effect of the drug at the hypothalamic level and consequently to an inhibition of dopamine decarboxylation in the tuberoinfunbdibular dopaminergic system. It is not possible to exclude, however, that benserazide could exert its biological activity through the production of active metabolites in vivo.",
author = "S. Ruggieri and P. Falaschi and M. Baldassarre and R. D'Urso and {De Giorgio}, G. and A. Rocco and A. Agnoli",
year = "1982",
language = "English",
volume = "8",
pages = "102--108",
journal = "Neuropsychobiology",
issn = "0302-282X",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease

AU - Ruggieri, S.

AU - Falaschi, P.

AU - Baldassarre, M.

AU - D'Urso, R.

AU - De Giorgio, G.

AU - Rocco, A.

AU - Agnoli, A.

PY - 1982

Y1 - 1982

N2 - Plasma prolactin (PRL) level modifications after acute administration of L-dopa, L-dopa plus carbidopa and L-dopa benserazide were studied in parkinsonian patients. PRL increase after benserazide was compared with PRL response after carbidopa at the same dosage in untreated parkinsonian patients. A further study of the hyperprolactinemic effect of benserazide was performed in vitro on isolated and dispersed rat pituitary cells. The data gathered indicate that benserazide-induced hyperprolactinemia in parkinsonian patients could be due to a direct effect of the drug at the hypothalamic level and consequently to an inhibition of dopamine decarboxylation in the tuberoinfunbdibular dopaminergic system. It is not possible to exclude, however, that benserazide could exert its biological activity through the production of active metabolites in vivo.

AB - Plasma prolactin (PRL) level modifications after acute administration of L-dopa, L-dopa plus carbidopa and L-dopa benserazide were studied in parkinsonian patients. PRL increase after benserazide was compared with PRL response after carbidopa at the same dosage in untreated parkinsonian patients. A further study of the hyperprolactinemic effect of benserazide was performed in vitro on isolated and dispersed rat pituitary cells. The data gathered indicate that benserazide-induced hyperprolactinemia in parkinsonian patients could be due to a direct effect of the drug at the hypothalamic level and consequently to an inhibition of dopamine decarboxylation in the tuberoinfunbdibular dopaminergic system. It is not possible to exclude, however, that benserazide could exert its biological activity through the production of active metabolites in vivo.

UR - http://www.scopus.com/inward/record.url?scp=0020052265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020052265&partnerID=8YFLogxK

M3 - Article

C2 - 7070643

AN - SCOPUS:0020052265

VL - 8

SP - 102

EP - 108

JO - Neuropsychobiology

JF - Neuropsychobiology

SN - 0302-282X

IS - 2

ER -